DiaSorin buys the American Luminex for 1.8 billion

Usually the opposite happens: a large foreign group that comes to Italy to go shopping. It is one of the concerns of the government, which is preparing to extend the scope of the golden power to avoid the risk of scaling against the tricolor jewels. In this case, the Italian DiaSorin, based in Saluggia, in the Vercelli area, has scored a blitz in the United States. The group led by CEO Carlo Rosa, a global leader in the field of in vitro diagnostics and present on five continents with twenty-six companies, acquired Luminex Corporation last night for $ 37 a share. The Austin, Texas-based firm’s valuation is around $ 1.8 billion. The overseas blitz, explains DiaSorin, will strengthen the positioning of the Italian group in the field of molecular diagnostics: with the operation, the Saluggia-based company will in fact access the technology and a multiplexing portfolio of molecular diagnostics, strengthening the current offer and expanding its presence in States. “We are thrilled with this transaction which we believe creates value for our shareholders and represents an exceptional opportunity for our future growth, positioning DiaSorin and Luminex as a unique combination of diagnostics specialists” explains CEO Rosa. “Luminex – he continues – is perfectly in line with our strategy and with the desire to strengthen our positioning in molecular diagnostics, to expand our presence in the US market and to create further value by providing solutions to the life science sector”. According to Achum “Homi” Shamir, president and CEO of Luminex, the merger will allow «to provide even more value to our customers».